Sat | Dec 2, 2023

Pfizer pill becomes 1st US-authorised home COVID treatment

Published:Wednesday | December 22, 2021 | 3:19 PM
This image provided by Pfizer in October 2021 shows the company's COVID-19 Paxlovid pills. United States health regulators on Wednesday, December 22, 2021, authorized the first pill against COVID-19, a Pfizer drug that Americans will be able to take at home to head off the worst effects of the virus. (Pfizer via AP)

WASHINGTON (AP) — United States health regulators on Wednesday authorised the first pill against COVID-19, a Pfizer drug that Americans will be able to take at home to head off the worst effects of the virus.

The long-awaited milestone comes as US cases, hospitalisations and deaths are all rising and health officials warn of a tsunami of new infections from the omicron variant that could overwhelm hospitals.

The drug, Paxlovid, is a faster, cheaper way to treat early COVID-19 infections, though initial supplies will be extremely limited.

All of the previously authorised drugs against the disease require an IV or an injection.

An antiviral pill from Merck also is expected to soon win authorisation.

But Pfizer's drug is all but certain to be the preferred option because of its mild side effects and superior effectiveness, including a nearly 90% reduction in hospitalisations and deaths among patients most likely to get severe disease.

“The efficacy is high, the side effects are low and it's oral.

It checks all the boxes,” said Dr. Gregory Poland of the Mayo Clinic. “You're looking at a 90% decreased risk of hospitalisation and death in a high-risk group — that's stunning.”

The Food and Drug Administration authorised Pfizer's drug for adults and children ages 12 and older with a positive COVID-19 test and early symptoms who face the highest risks of hospitalisation.

That includes older people and those with conditions like obesity and heart disease.

Children eligible for the drug must weigh at least 88 pounds (40 kilogrammes).

The pills from both Pfizer and Merck are expected to be effective against omicron because they don't target the spike protein where most of the variant's worrisome mutations reside.

Pfizer currently has 180,000 treatment courses available worldwide, with roughly 60,000 to 70,000 allocated to the US Federal health officials are expected to ration early shipments to the hardest-hit parts of the country. Pfizer said the small supply is due to the manufacturing time — currently about nine months.

The company says it can halve production time next year.

The US government has agreed to purchase enough Paxlovid to treat 10 million people.

Pfizer says it's on track to produce 80 million courses globally next year, under contracts with the UK, Australia and other nations.

Health experts agree that vaccination remains the best way to protect against COVID-19.

But with roughly 40 million American adults still unvaccinated, effective drugs will be critical to blunting the current and future waves of infection.

Follow The Gleaner on Twitter and Instagram @JamaicaGleaner and on Facebook @GleanerJamaica. Send us a message on WhatsApp at 1-876-499-0169 or email us at onlinefeedback@gleanerjm.com or editors@gleanerjm.com.